We are pleased to see the GranuFlo recall litigation moving forward, as we continue to hear from dialysis patients who suffered heart attacks, stroke, cardiac arrest, and other catastrophic heart side effects, allegedly due to GranuFlo or NaturaLyte.
New York, New York (PRWEB) July 23, 2013
GranuFlo lawsuit claims filed in the wake of the recent recall of GranuFlo and NaturaLyte dialysis concentrates are moving forward in a federal multidistrict litigation now underway in U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. According to court documents, the judge overseeing the GranuFlo recall litigation issued an Order on July 16th that established the proceeding’s plaintiffs' executive and steering committees. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
“We are pleased to see the GranuFlo recall litigation moving forward, as we continue to hear from dialysis patients who suffered heart attacks, stroke, cardiac arrest, and other catastrophic heart side effects, allegedly due to GranuFlo or NaturaLyte,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free GranuFlo lawsuit evaluations to dialysis patients who may have been harmed by these drugs.
GranuFlo and NaturaLyte Recall
Marketed by Fresenius Medical Care, GranuFlo and NaturaLyte are used during dialysis to reduce the amount of acid in the blood. In March 2012, Fresenius issued an “Urgent Product Notification” to its customer clinics warning of possible heart risks associated with the products, which would later be deemed a Class I GranuFlo recall by the U.S. Food & Drug Administration (FDA). Class I recalls are the agency’s most serious type, and are issued when a medical product poses a significant risk of serious injury or death.*
More than 300 dialysis lawsuit claims involving GranuFlo and NaturaLyte are now pending in the District of Massachusetts. According to court documents, plaintiffs allege Fresenius knew or should have known of the propensity of GranuFlo and NaturaLyte to cause injury. They further allege the Company failed to provide adequate instructions and warnings for their use.
According to a report from The New York Times, Fresenius Medical Care treats more than a third of the estimated 400,000 Americans receiving dialysis and is the leading supplier of dialysis machines and disposable products. GranuFlo and NaturaLyte were widely used at Fresenius’s own dialysis clinics, and were also used to treat an estimated 125,000 patients at clinics outside of the Fresenius network. Last summer, the FDA launched an investigation into the company’s handling of the GranuFlo recall, after learning that Fresenius had issued a memo in November 2011 to its own clinics that warned of the heart risks associated with GranuFlo and NaturaLyte, and advised doctors to adjust their dosage to avoid these dangers.**
Patients who suffered heart attacks, sudden cardiac death, and other catastrophic heart side effects within 48 hours of a dialysis treatment with GranuFlo and NaturaLyte may be entitled to file a Granuflo lawsuit to obtain compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about the GranuFlo recall by visiting Bernstein Liebhard LLP’s website. For additional information, contact a lawyer at Bernstein Liebhard LLP today by calling 800-511-5092.
*fda.gov/MedicalDevices/Safety/ListofRecalls/ucm309990.htm; FDA, March 29, 2013
**nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP